(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;2,3-dihydroxybutanedioic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;2,3-dihydroxybutanedioic acid
• 化学式: C23H26FNO9
• 分子量: 479.5
• InChiKey: VYGOTYYIODMKGC-RVXRQPKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  155
• 氢给体数：
  5
• 氢受体数：
  11

文献信息

• Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or derivative thereof
  申请人：Lee Joon Sang

  公开号：US20060063747A1

  公开（公告）日：2006-03-23

  Disclosed herein is a paroxetine cholate or cholic acid derivative salt and a composition comprising paroxetine and cholic acid or a derivative thereof. Further disclosed is a pharmaceutical composition comprising the paroxetine salt or the composition. The pharmaceutical composition can be formulated into an oral preparation for swallowing without water as an orally disintegrating tablet for paroxetine.

  本文披露了帕罗西汀胆酸盐或胆酸衍生物盐以及包含帕罗西汀和胆酸或其衍生物的组合物。进一步披露了包含帕罗西汀盐或该组合物的药物组合物。该药物组合物可以制成口服制剂，作为帕罗西汀的口服崩解片，可直接吞咽而无需水。
• METHOD OF PRODUCING PAROXETINE HYDROCHLORIDE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1135382A1

  公开（公告）日：2001-09-26
• US7229980B2
  申请人：——

  公开号：US7229980B2

  公开（公告）日：2007-06-12
• [EN] METHOD OF PRODUCING PAROXETINE HYDROCHLORIDE<br/>[FR] PROCEDE DE FABRICATION D'HYDROCHLORURE DE PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000032593A1

  公开（公告）日：2000-06-08

  The present invention relates to a new process for preparing pharmaceutically active compounds and intermediates therefor. The (-) trans isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxymethyl)piperidine (paroxetine) is an important compound having antidepressant and anti-Parkinson properties. This compound is used in therapy as the hydrochloride salt to treat inter alia depression, obsessive compulsive disorder (OCD) and panic. There is described herein an improved process for its preparation which avoids the generation of impurities caused by the use of strong mineral acid to form the salt.
• [EN] PAROXETINE<br/>[FR] PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001012624A1

  公开（公告）日：2001-02-22

  Processes are disclosed for preparing paroxetine free base in substantially pure form. The free base may be combined with a pharmaceutically acceptable diluent and/or converted in-situ to a pharmaceutically acceptable salt.